Postpartum Depression | Treatment Algorithms: Claims Data Analysis | US | 2024

Postpartum depression (PPD) refers to depression experienced after childbirth in women. The PPD drug market consists of very limited approved treatment options specifically for PPD, and hence, the drugs used for major depressive disorder are often used off-label for the management of PPD patients, which include multiple, well-established drug classes such as SSRIs, SNRIs, mixed serotonin modulators, atypical antipsychotics etc. The high unmet need for therapies specifically targeting PPD gives the first approved branded agent, Zulresso (Sage Therapeutics), an opportunity to be incorporated into the PPD treatment algorithm and creates opportunities for the new, oral drug Zurzuvae (Sage Therapeutics) and for future drug developers. Given the limited treatment options for physicians, it is valuable for drug marketers and developers to understand physicians’ actual prescribing behavior in PPD currently. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing an insight into the current PPD treatment landscape.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PPD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PPD patients?
• How has Zulresso been integrated into the treatment algorithm, and what is its source of business?
• What percentage of PPD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of PPD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: Zulresso, SSRIs, SNRIs, bupropion, atypical antipsychotics, mixed serotonin modulators, tricyclic antidepressants, benzodiazepines, anxiolytics, etc.

Key analyses

• Brand / therapy usage across longitudinal patient sample
• Newly diagnosed patient analysis
• Treatment initiation and progression
• Line of therapy analysis
• Combination therapy analysis
• Source of business for recently treated patients
• Persistency and compliance analysis
• Product-level patient flow charts

Key features: Dashboard featuring interactive visuals, easy navigation, and expanded analyses.